CompletedNot Applicable

A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia

Greece67 participantsStarted 2012-04

Plain-language summary

This observational study will evaluate the safety and efficacy of rituximab in combination with chemotherapy in first- and second-line treatment of participants with cluster of differentiation 20 (CD20)-positive B-cell chronic lymphocytic leukemia. Data will be collected from eligible participants receiving rituximab according to the Summary of Product Characteristics (SPC) during 6 months of treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Participants with CD20-positive B-cell chronic lymphocytic leukemia eligible for first-line or second-line therapy according to the approved SPC Exclusion Criteria: \- Contraindications to rituximab therapy according to the approved SPC

What they're measuring

Percentage of Participants With Adverse Events (AEs)

Timeframe: Baseline up to 24 months

Trial details

NCT IDNCT01609023

SponsorHoffmann-La Roche

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2015-11

Results submitted2017-03-28

View on ClinicalTrials.gov More Lymphocytic Leukemia, Chronic trials